Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 159 for your search:
Cancer Type/Condition:
Ovarian epithelial cancer
Stage/Subtype:
stage IV ovarian epithelial cancer
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
Adult
Sponsor:
Other
Protocol IDs:
RCOG-MRC-CHORUS
, EU-20350, ISRCTN74802813, NCT00075712
2.
Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)
Phase:
Phase III, Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
Levosta-CBF-02/04
, NCT00215007
3.
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
Phase:
Phase III, Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 85
Sponsor:
Other
Protocol IDs:
20050113
, NCT00243685
4.
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 79
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AMT/P2CA/001
, LC003AURON2005, NCT00332280
5.
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
Phase:
Phase III, Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
WIRB 20060042
, NCT00443196
6.
Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CAN-NCIC-OV21
, OV.21, UCL08/0379, GEICO-0902, NCT00993655
7.
Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
NCI
Protocol IDs:
GOG-0212
, NCT00108745
8.
A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-Risk Haematology Patients
Phase:
Phase III
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 to 80
Sponsor:
Other
Protocol IDs:
55/05
, ALLG SC01, NHMRC Project Grant 331305, NCT00163722
9.
Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
12 to 65
Sponsor:
Other
Protocol IDs:
PROGAST
, NCT00180089
10.
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
MREC-ICON7
, EUDRACT-2005-003929-22, ISRCTN91273375, ROCHE-MREC-ICON7, EU-20730, ICON7, MREC-06/MRE02/52, NCT00483782
11.
Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
KTN32313R
, NCT00477282
12.
A Quality of Life Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
MITO-7
, EudraCT number 2008-001754-40, NCT00660842
13.
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
GOG-OVM0703
, GOG OVM0703, OVM0703, NCT00693342
14.
Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
20 to 65
Sponsor:
Other
Protocol IDs:
I473
, NCT00715286
15.
Pazopanib in Treating Patients With Metastatic Soft Tissue Sarcoma That Has Relapsed or Not Responded to Treatment
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
EORTC-62072
, EORTC 62072, EU-20887, NCT00794521, PALETTE, GSK-VEG110727, EUDRACT-2008-001307-33
16.
CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
IP-CAT-AC-03
, NCT00822809
17.
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
GOG-0255
, GOG-0255, NCT00857545
18.
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
110655
, AGO-OVAR16, NCT00866697
19.
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
GOG-0252
, GOG -0252, NCT00951496
20.
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
MO22224
, 2009-011400-33, NCT00976911
21.
BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
1199.15
, EudraCT: 2008-006831-10, AGO-OVAR12, NCT01015118
22.
Pentostatin and Donor White Blood Cells in Preventing Graft Rejection in Cancer Patients Who Have Undergone Donor Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
FHCRC-1825.00
, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
23.
Ixabepilone and Liposomal Doxorubicin in Treating Women With Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer or Metastatic Breast Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
AECM-0504007857
, NCI-7229, 7229, NCT00182767
24.
Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
YALE-HIC-27640
, YALE-012705, NCT00303888
25.
Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
CT/06.14
, NCT00429559
Select All on Page
1
Help with Results
